Main menu

Advancing RNA liquid biopsy via nanopore sequencing


Webinar Overview

RNA liquid biopsies enable minimally invasive systemic profiling of tissues and organs through cell-free RNAs present in the blood. In this study, nanopore sequencing revealed thousands of full-length cell-free RNAs in pancreatic and esophageal cancer patients.

Using COMPLETE-seq technology, high levels of repetitive cell-free RNAs, particularly SINE-derived RNAs, were detected in pancreatic cancer patients. These repetitive cell-free RNA features improved the performance of machine-learning models for cancer classification.

Importantly, nanopore sequencing uncovered over 250,000 novel cell-free RNAs, highlighting the potential of long-read sequencing for identifying novel biomarkers of health and disease.

Viewers of this webinar learned:

  • RNA liquid biopsy technology enables highly sensitive and specific cancer detection in a minimally invasive way

  • Repetitive cell-free RNAs are enriched in cancer patients and can be leveraged to improve disease classification

  • Nanopore sequencing reveals full-length cell-free RNAs, including thousands of novel and disease-specific RNAs

Authors: Daniel Kim, PhD (Assistant Professor at University of California, Santa Cruz), Ellie Juarez, PhD (Market Segment Manager for Oncology, Oxford Nanopore Technologies)

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Nanopore technology

Subscribe to Nanopore updates Resources and publications What is the Nanopore Community

About Oxford Nanopore

News Company timeline Sustainability Leadership team Media resources & contacts For investors For partners Working at Oxford Nanopore Current vacancies Commercial information BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
English flag